|GI-Cell partners with Helixmith and Cartexell to develop cell therapy technology|
View : 768 | 2022-04-29
GI-Cell partners with Helixmith and Cartexell to develop cell therapy technology
GI-Cell, a South Korean developer of immune cell therapy products, has partnered with DNA and protein-based therapeutics companies to jointly develop cell therapy technologies involving immune cells to enhance disease-fighting abilities of target patients.
GI-Cell has signed a memorandum of understanding with Helixmith and Cartexell to develop cell therapy medicine based on an immune cell expander platform. GI-Cell hopes to target the global immune cell therapy market through collaboration.
|Previous post||BIO-EUROPE SPRING 2022_GICELL corporate presentation|
|Next post||GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy|